Single nucleotide polymorphisms of toll-like receptor 4 decrease the risk of development of hepatocellular carcinoma

PLoS ONE

Volumn 6, Issue 4, 2011, Pages

  Minmin, Shi ^a   Xiaoqian, Xu ^b   Hao, Chen ^a   Baiyong, Shen ^a   Xiaxing, Deng ^a   Junjie, Xie ^a   Xi, Zhan ^a   Jianquan, Zhao ^a   Songyao, Jiang ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

TOLL LIKE RECEPTOR 4; TLR4 PROTEIN, HUMAN;

5' UNTRANSLATED REGION; ADULT; ARTICLE; CANCER RISK; CASE CONTROL STUDY; CONTROLLED STUDY; FEMALE; GENETIC ANALYSIS; GENOTYPE; HAPLOTYPE; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; INTRON; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; RISK REDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; WILD TYPE; BIOLOGICAL MODEL; COHORT ANALYSIS; GENE EXPRESSION REGULATION; GENETIC PREDISPOSITION; GENETIC VARIABILITY; GENETICS; LIVER TUMOR; MUTATION; RISK; TIME;

5' UNTRANSLATED REGIONS; CARCINOMA, HEPATOCELLULAR; CASE-CONTROL STUDIES; COHORT STUDIES; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC PREDISPOSITION TO DISEASE; GENETIC VARIATION; HUMANS; INTRONS; LIVER NEOPLASMS; MALE; MODELS, GENETIC; MUTATION; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK; TIME FACTORS; TOLL-LIKE RECEPTOR 4;

EID: 79955764344     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0019466     Document Type: Article

References (37)

1. Aderem A, Ulevitch RJ, (2000) Toll-like receptors in the induction of the innate immune response. Nature 406: 782-787.
2. Johnson GB, Brunn GJ, Platt JL, (2004) Ctting edge: an endogenous pathway to systemic inflammatory response syndrome (SIRS)-like reactions through Toll-like receptor 4. J Immunol 172: 20-24.
3. Armstrong L, Medford AR, Hunter KJ, Uppington KM, Millar AB, (2004) Differential expression of Toll-like receptor (TLR)-2 and TLR-4 on monocytes in human sepsis. Clin Exp Immunol 136: 312-319.
4. Härter L, Mica L, Stocker R, Trentz O, Keel M, (2004) Increased expression of toll-like receptor-2 and-4 on leukocytes from patients with sepsis. Shock 22: 403-409.
5. Kurt-Jones EA, Popova L, Kwinn L, Haynes LM, Jones LP, et al. (2000) Pattern recognition receptors TLR4 and CD14 mediate response to respiratory syncytial virus. Nat Immunol 1: 398-401.
6. El-Omar EM, Ng MT, Hold GL, (2008) Polymorphisms in Toll-like receptor genes and risk of cancer. Oncogene 27: 244-52.
7. Song J, Kim DY, Kim CS, Kim HJ, Lee DH, et al. (2009) The association between Toll-like receptor 4 (TLR4) polymorphisms and the risk of prostate cancer in Korean men. Cancer Genet Cytogenet 190: 88-92.
8. Zheng SL, Augustsson-Bälter K, Chang B, Hedelin M, Li L, et al. (2004) Sequence variants of toll-like receptor 4 are associated with prostate cancer risk: results from the CAncer Prostate in Sweden Study. Cancer Res 64: 2918-2922.
9. Chen YC, Giovannucci E, Lazarus R, Kraft P, Ketkar S, et al. (2005) Sequence variants of Toll-like receptor 4 and susceptibility to prostate cancer. Cancer Res 65: 11771-11778.
10. Hold GL, Rabkin CS, Chow WH, Smith MG, Gammon MD, et al. (2007) A functional polymorphism of toll-like receptor 4 gene increases risk of gastric carcinoma and its precursors. Gastroenterology 132: 905-912.
11. Hishida A, Matsuo K, Goto Y, Mitsuda Y, Hiraki A, et al. (2009) Toll-like receptor 4 +3725 G/C polymorphism, Helicobacter pylori seropositivity, and the risk of gastric atrophy and gastric cancer in Japanese. Helicobacter 14: 47-53.
12. Johnson TR, Parker RA, Johnson JE, Graham BS, (2003) IL-13 is sufficient for respiratory syncytial virus G glycoprotein-induced eosinophilia after respiratory syncytial virus challenge. J Immunol 170: 2037-2045.
13. Isogawa M, Robek MD, Furuichi Y, Chisari FV, (2005) Toll-like receptor signaling inhibits hepatitis B virus replication in vivo. J Virol 79: 7269-7272.
14. Schwabe RF, Seki E, Brenner DA, (2006) Toll-like receptor signaling in the liver. Gastroenterology 130: 1886-900.
15. Parkin DM, (2001) Global cancer statistics in the year 2000. Lancet Oncol 2: 533-543.
16. El-Serag HB, Rudolph KL, (2007) Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 132: 2557-2576.
17. Wei XQ, Guo YW, Liu JJ, Wen ZF, Yang SJ, et al. (2008) The significance of Toll-like receptor 4 (TLR4) expression in patients with chronic hepatitis B. Clin Invest Med 31: E123-130.
18. Ganem D, Prince AM, (2004) Hepatitis B virus infection-natural history and clinical consequences. N Engl J Med 350: 1118-1129.
19. Prince JM, Levy RM, Yang R, Mollen KP, Fink MP, et al. (2006) Toll-like receptor-4 signaling mediates hepatic injury and systemic inflammation in hemorrhagic shock. J Am Coll Surg 202: 407-417.
20. Wang H, Li ZY, Wu HS, Wang Y, Jiang CF, et al. (2007) Endogenous danger signals trigger hepatic ischemia/reperfusion injury through toll-like receptor 4/nuclear factor-kappa B pathway. Chin Med J (Engl) 120: 509-514.
21. Uesugi T, Froh M, Arteel GE, Bradford BU, Thurman RG, (2001) Toll-like receptor 4 is involved in the mechanism of early alcohol induced liver injury in mice. Hepatology 34: 101-108.
22. Poltorak A, He X, Smirnova I, Liu MY, Van Huffel C, et al. (1998) Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science 282: 2085-2088.
23. Levy RM, Mollen KP, Prince JM, Kaczorowski DJ, Vallabhaneni R, et al. (2007) Systemic inflammation and remote organ injury following trauma require HMGB1. Am J Physiol Regul Integr Comp Physiol 293: R1538-1544.
24. Imai Y, Kuba K, Neely GG, Yaghubian-Malhami R, Perkmann T, et al. (2008) Identification of oxidative stress and Toll-like receptor 4 signaling as a key pathway of acute lung injury. Cell 133: 235-249.
25. Cheng I, Plummer SJ, Casey G, Witte JS, (2007) Toll-like receptor 4 genetic variation and advanced prostate cancer risk. Cancer Epidemiol Biomarkers Prev 16: 352-355.
26. van der Velden AW, Thomas AA, (1999) The role of the 5′ untranslated region of an mRNA in translation regulation during development. Int J Biochem Cell Biol 31: 87-106.
27. Ma WJ, Lv GD, Zheng ST, Huang CG, Liu Q, et al. (2010) DNA polymorphism and risk of esophageal squamous cell carcinoma in a population of North Xinjiang, China. World J Gastroenterol 16: 641-647.
28. Scola L, Giacalone A, Marasà L, Mirabile M, Vaccarino L, et al. (2009) Genetic determined downregulation of both type 1 and type 2 cytokine pathways might be protective against pancreatic cancer. Ann N Y Acad Sci 1155: 284-288.
29. Brown I, Halliday S, Greig H, Heys SD, Wallace HM, et al. (2009) Genetic polymorphism in ornithine decarboxylase and risk of breast cancer. Fam Cancer 8: 307-311.
30. Giess M, Lattrich C, Springwald A, Goerse R, Ortmann O, et al. (2010) GPR30 gene polymorphisms are associated with progesterone receptor status and histopathological characteristics of breast cancer patients. J Steroid Biochem Mol Biol 118: 7-12.
31. George Priya Doss C, Sudandiradoss C, Rajasekaran R, Choudhury P, Sinha P, et al. (2008) Applications of computational algorithm tools to identify functional SNPs. Funct Integr Genomics 8: 309-316.
32. Ding Y, Larson G, Rivas G, Lundberg C, Geller L, et al. (2008) Strong signature of natural selection within an FHIT intron implicated in prostate cancer risk. PLoS One 2008; 3: e3533.
33. Prentice RL, Huang Y, Hinds DA, Peters U, Cox DR, et al. (2010) Variation in the FGFR2 gene and the effect of a low-fat dietary pattern on invasive breast cancer. Cancer Epidemiol Biomarkers Prev 19: 74-79.
34. Karami S, Brennan P, Rosenberg PS, Navratilova M, Mates D, et al. (2009) Analysis of SNPs and haplotypes in vitamin D pathway genes and renal cancer risk. PLoS One 4: e7013.
35. Jou YS, Lo YL, Hsiao CF, Chang GC, Tsai YH, et al. (2009) Association of an EGFR intron 1 SNP with never-smoking female lung adenocarcinoma patients. Lung Cancer 64: 251-256.
36. Greene FL, (2002) AJCC cancer staging manual. Chicago Springer.
37. Wacholder S, Chanock S, Garcia-Closas M, El Ghormli L, Rothman N, (2004) Assessing the probability that a positive report is false: an approach for molecular epidemiology studies. J Natl Cancer Inst 96: 434-442.